Drug Trial Radar · NCT06008106
Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma
Last checked: Nov 19, 2026Latest source record: Jun 28, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
165
Planned (sponsor's estimate)
Start
Nov 2, 2023
Primary completion
Sep 22, 2027
Study completion Sep 22, 2027
Sponsor
- Lead sponsor
- Shanghai Kechow Pharma, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 23, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, two-arm, open-label, randomized controlled phase III clinical trial to evaluate the efficacy and safety of tunlametinib capsule in comparison with the combination chemotherapy of investigator's choice in advanced melanoma patients with NRAS mutation who have received immunotherapy before. Subjects were stratified according to the baseline lactate dehydrogenase level and chemotherapy.
Conditions
- Melanoma
Interventions
tunlametinibDrug
12mg BID
paclitaxel +carboplatin, or temozolomide +cisplatin, or dacarbazine +cisplatinDrug
according to investigators' suggestion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free Survival(PFS)Time frame: up to 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Cancer Hospital
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.